Safety and efficacy of P2B001 (low dose combination of extended-release pramipexole and rasagiline) in patients with early Parkinson’s disease: Subgroup analyses from a randomized, controlled trial
Objective: Evaluate the efficacy and safety of P2B001 for different subgroups of patients with early Parkinson’s disease (PD). Background: P2B001 is an investigational, fixed low-dose,…P2B001 in the management of untreated PD. Results from a randomized, double-blind, double-dummy controlled trial
Objective: Evaluate the efficacy and safety of P2B001 compared with its components and with Extended-Release pramipexole (ER-PPX, calibration arm) in untreated PD. Background: P2B001 is…Epidemiology of Impulse Control Disorders and Association with Dopamine Agonist Exposure in the United States Military
Objective: Evaluate the epidemiology of impulse control disorders in the US Military and their association with dopamine agonist exposure. Background: Impulse control disorders (ICDs) are…Pramipexole regulates the depressive-like symptom through dopamine D3 not dopamine D2 receptor in a mouse model of Parkinson’s disease
Objective: The aim of this study is to understand if the antidepressant effect of pramipexole is mediated by D2R or D3R in a mouse model…Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: a post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate opicapone’s (OPC) efficacy in levodopa-treated Parkinson’s Disease (PD) patients with or without concurrent pramipexole use (CPU). Background: OPC, a once-daily COMT inhibitor,…Clinical characterization of Pramipexole induced edema and skin reaction in Parkinson’s Disease (PD) after one year of follow up
Objective: We report four patients with PD treated several years with irregular and progressively higher doses of pramipexole who presented with extensive chronic bilateral lower…Basal Ganglia and Limbic Striatal Regions are Differentially Affected by Pramipexole: D3 receptor – Mediated Changes in Markers of Synaptic Strength
Objective: To determine whether pramipexole (PPX) differentially upregulates AMPA receptor trafficking in limbic vs. motor striatal regions of rats. Background: Impulse control disorders (ICD) are…Slow Release Fixed Dose Combination of Low Doses Pramipexole and Rasagiline (P2B001) for the Treatment of Early Parkinson’s Disease (PD).
Objective: Evaluation of the efficacy and safety of a slow release low dose combination of pramipexole (PPX) and rasagiline (RAS) (P2B001) in a prospective double-blind…Implications of direct and indirect costs in health-related quality of life in Parkinson’s disease: A cross-sectional study in Mexico
Objective: To evaluate the association of direct and indirect costs of Parkinson's disease (PD) and health-related quality of life (HRQoL) in a Mexican population. Background:…AntiParkinsonian effects of AG-0029 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease
Objective: To assess the motor functions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques following acute administration of AG-0029. Background: Parkinson's disease (PD), in which there is widespread degeneration…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.